356,528 Shares in Shattuck Labs, Inc. $STTK Bought by Deutsche Bank AG

Key Points

• Deutsche Bank acquired 356,528 shares of Shattuck Labs in the second quarter, worth approximately $2.47 million. Institutional investors collectively own 58.74% of the company.
• Analyst sentiment is broadly positive: Shattuck Labs has a consensus “Buy” rating and an average price target of $12.78, with recent targets ranging from $7 to $18.
• STTK opened at $7.65, near its 52-week high of $8.33, while the company reported quarterly EPS of negative $0.12, in line with estimates. Its lead program is developing a fentanyl-targeting immunotherapeutic vaccine.

Deutsche Bank AG purchased a new position in Shattuck Labs, Inc. (NASDAQ:STTK - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 356,528 shares of the company's stock, valued at approximately $2,474,000. Deutsche Bank AG owned about 0.46% of Shattuck Labs as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the business. AQR Capital Management LLC lifted its stake in shares of Shattuck Labs by 265.4% in the 1st quarter. AQR Capital Management LLC now owns 43,169 shares of the company's stock valued at $41,000 after acquiring an additional 31,355 shares during the last quarter. Jacobs Levy Equity Management Inc. purchased a new position in Shattuck Labs in the 1st quarter worth approximately $81,000. Acadian Asset Management LLC increased its stake in Shattuck Labs by 27.6% in the 1st quarter. Acadian Asset Management LLC now owns 257,345 shares of the company's stock worth $243,000 after purchasing an additional 55,687 shares during the period. Qube Research & Technologies Ltd bought a new stake in Shattuck Labs in the second quarter valued at approximately $44,000. Finally, Jane Street Group LLC lifted its position in Shattuck Labs by 2,510.8% in the second quarter. Jane Street Group LLC now owns 289,671 shares of the company's stock valued at $229,000 after purchasing an additional 278,576 shares during the last quarter. 58.74% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the stock. Citigroup upgraded shares of Shattuck Labs from a "neutral" rating to a "buy" rating and set a $7.00 target price on the stock in a report on Friday, June 5th. TD Cowen upgraded shares of Shattuck Labs to a "strong-buy" rating in a research report on Monday. Leerink Partners initiated coverage on shares of Shattuck Labs in a research note on Monday, July 20th. They set an "outperform" rating and a $16.00 price objective for the company. Raymond James Financial initiated coverage on shares of Shattuck Labs in a report on Monday. They set a "strong-buy" rating and a $18.00 target price for the company. Finally, Weiss Ratings upgraded Shattuck Labs from a "sell (e+)" rating to a "sell (d-)" rating in a report on Tuesday, June 16th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average price target of $12.78.

Insider Buying and Selling

In related news, insider Abhinav A. Shukla sold 23,365 shares of the firm's stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $7.08, for a total transaction of $165,424.20. Following the completion of the transaction, the insider owned 86,380 shares of the company's stock, valued at $611,570.40. This trade represents a 21.29% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Clay B. Siegall acquired 62,500 shares of the stock in a transaction on Tuesday, June 9th. The shares were bought at an average price of $4.00 per share, with a total value of $250,000.00. Following the purchase, the director directly owned 318,608 shares of the company's stock, valued at $1,274,432. The trade was a 24.40% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have sold 53,875 shares of company stock worth $379,305 in the last 90 days. Insiders own 8.79% of the company's stock.

Shattuck Labs Price Performance

NASDAQ:STTK opened at $7.65 on Friday. The firm's 50-day moving average price is $7.00 and its 200-day moving average price is $6.20. The company has a market capitalization of $767.75 million, a PE ratio of -15.00 and a beta of 1.08. Shattuck Labs, Inc. has a 1-year low of $0.97 and a 1-year high of $8.33.

Shattuck Labs (NASDAQ:STTK - Get Free Report) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.12) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.12). Equities analysts anticipate that Shattuck Labs, Inc. will post -0.44 EPS for the current fiscal year.

Shattuck Labs Profile

Shattuck Labs, Inc NASDAQ: STTK is a clinical‐stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten‐carrier conjugate technology designed to generate high‐affinity drug‐specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood‐brain barrier.

The company's lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities.

Want to see what other hedge funds are holding STTK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Shattuck Labs, Inc. (NASDAQ:STTK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source